Atomoxetine
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
- Atomoxetine
- Pharmacist Assessment Report
- Atomoxetine: From Attention Deficit Hyperactivity Disorder to Specific Developmental Disorder
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- India Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Atomoxetine: From Attention Deficit Hyperactivity Disorder to Specific Developmental Disorder
One-Sentence Summary
Atomoxetine is a non-stimulant medicine originally used to treat attention deficit hyperactivity disorder (ADHD). The TxGNN model predicts it may be effective for specific developmental disorder (for example, learning disabilities), but there are no registered clinical trials and the 14 publications compiled for this report are mostly about ADHD in patients with other conditions, not about the developmental disorder itself.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Attention deficit hyperactivity disorder (ADHD), including the inattentive type |
| Predicted New Indication | Specific developmental disorder |
| TxGNN Prediction Score | 1.0000 |
| Evidence Level | L4 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
The original indication comes from the TxGNN model (deep learning), because the Indian licence records contain no approved indication text; the score comes from the model and may reflect similarities the model learned between related diseases, not biological evidence.
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Atomoxetine is known to be a selective norepinephrine reuptake inhibitor, and it is a non-stimulant treatment for ADHD.
Specific developmental disorders, such as learning disabilities, often occur together with ADHD. Any benefit from atomoxetine is therefore more likely to be indirect. Better attention and executive function could help patients, but this would not mean the learning disorder itself is treated.
The available literature does not test atomoxetine against the developmental disorder directly. It consists of ADHD studies in patients with other conditions (autism, bipolar disorder), an EEG study, and drug-interaction reviews. The prediction is therefore plausible as an indirect, symptom-level link but is not supported by direct evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39701638 | 2025 | Systematic review / network meta-analysis | The Lancet Psychiatry | Compares drug, psychological and neurostimulation treatments for adult ADHD; the aim was to fill gaps in comparative benefit and harm |
| 30653855 | 2019 | Systematic review / meta-analysis | Autism Research | Three placebo-controlled randomized trials (241 children) of atomoxetine for ADHD symptoms in children with autism |
| 27721971 | 2016 | Review | Therapeutic Advances in Psychopharmacology | Reviews atomoxetine for ADHD with common comorbidities (mood, anxiety, developmental, substance use) |
| 33012168 | 2021 | Cohort | Clinical EEG and Neuroscience | Quantitative EEG in childhood ADHD and learning disabilities |
| 35485452 | 2022 | Cohort (retrospective) | Neuropsychopharmacology Reports | Factors associated with atomoxetine efficacy in adult ADHD; long-term efficacy about 40% at 6 months |
| 25545605 | 2015 | Systematic review | Journal of Affective Disorders | Comorbidity in paediatric bipolar disorder, including its treatment |
| 31425490 | 2020 | Review | Therapeutic Drug Monitoring | Potential interactions between synthetic cathinones and prescription drugs |
| 32022784 | 2020 | Systematic review | Therapeutic Drug Monitoring | Potential interactions between novel phenethylamines and prescription drugs |
| 42675180 | 2026 | Imaging cohort | Nature Biomedical Engineering | Structural connectivity deviations in youths with ADHD predict symptom and treatment outcomes |
| 39514707 | 2024 | Case report | Journal of Developmental and Behavioral Pediatrics | Atomoxetine in an 11-year-old with ADHD, anxiety, depression and suicidality |
None of these studies tests atomoxetine for a specific developmental disorder.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 8430 | Atomoxet 25mg Tablet | Strip of 10 tablets | Not stated in licence record |
| 14593 | Atmosril 18mg Tablet | Strip of 10 tablets | Not stated in licence record |
| 221886 | Tomkid 40mg Tablet | Strip of 10 tablets | Not stated in licence record |
| 7887 | Attentin 25mg Tablet | Strip of 10 tablets | Not stated in licence record |
| 221868 | Tomoxetin 25mg Capsule | Strip of 10 capsules | Not stated in licence record |
There are 20 valid single-ingredient registrations in total, with no cancelled ones. They cover tablets, capsules and sachets, and the holders include Sun Pharmaceutical, Torrent Pharmaceuticals and Alkem Laboratories.
Safety Considerations
Package insert warnings and contraindications were not available for this report, so please refer to the package insert for safety information.
- Disease-level contraindication signals (knowledge graph, not label text): Cardiovascular conditions (hypertension, orthostatic hypotension, coronary artery disease, myocardial infarction, stroke and cerebrovascular disorders, heart conduction disease, sudden cardiac arrest); psychiatric conditions (bipolar disorder, psychotic and schizoaffective disorders); epilepsy; liver and gallbladder disease; hyperbilirubinaemia and Gilbert syndrome; and angle-closure glaucoma.
- Drug Interactions: 196 interactions were identified. Major interactions include cisapride and dolasetron. Moderate ones include bupropion, cimetidine, clarithromycin, epinephrine, ephedrine, famotidine, fenfluramine and loperamide.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction score is very high, but it is a model prediction with no registered trials and no studies that test atomoxetine for specific developmental disorders directly. Any benefit would probably be indirect, through ADHD symptoms.
To proceed, the following is needed:
- Direct clinical evidence, such as a controlled trial in patients with specific developmental disorders, including outcomes beyond ADHD symptoms
- Detailed mechanism of action data
- Package insert warnings and contraindications from the Indian regulator, to complete a safety screening
- A clear definition of the target population, because the benefit may be limited to patients who also have ADHD
- A review of the cardiovascular and psychiatric contraindication signals and the major drug interactions for the intended population
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.